

## SHORT COMMUNICATION

# The killer immunoglobulin-like receptor KIR3DL1 in combination with *HLA-Bw4* is protective against multiple sclerosis in African Americans

JA Hollenbach<sup>1</sup>, MJ Pando<sup>2</sup>, SJ Caillier<sup>1</sup>, P-A Gourraud<sup>1,3</sup> and JR Oksenberg<sup>1</sup>

We investigated the role of the *KIR* loci and their *HLA* class I ligands in a large cohort of African American multiple sclerosis (MS) patients ( $N=907$ ) and controls ( $N=1456$ ). No significant differences in carrier frequencies for any *KIR* locus or haplotype were observed between cases and controls. However, examination of *KIR* in the context of their cognate *HLA* ligands revealed a strong protective effect for *KIR3DL1* in combination with *HLA-A* and *-B* alleles bearing the Bw4 motif ( $P=10^{-8}$ ; odds ratio (OR)=0.60, confidence interval (CI)=0.50–0.71) and the Bw4 ligand alone ( $P<10^{-6}$ ; OR=0.63, CI=0.53–0.75). The observed effect cannot be explained by either a specific *HLA-B* allele or by linkage disequilibrium with *HLA-DRB1* or *HLA-A*. The protective effect was observed only in individuals who were not positive for the MS risk allele *HLA-DRB1\*15:01* ( $P<10^{-6}$ ; OR=0.61, CI=0.51–0.74). Our study, the first investigation of *KIR* and MS in African Americans, confirms and refines previous findings in a European cohort.

*Genes and Immunity* (2016) 17, 199–202; doi:10.1038/gene.2016.5; published online 11 February 2016

## INTRODUCTION

The important role of variation in genes of the human leukocyte antigen (*HLA*) complex in genetic predisposition to multiple sclerosis (MS) has long been recognized. However, in addition to their role in antigen presentation to T cells, *HLA* class I molecules also serve as ligands for killer immunoglobulin-like (KIR) molecules. An ever-increasing pace of investigation over the last decade has demonstrated definitively that KIR receptors play critical roles in transplantation success and disease pathogenesis.<sup>1–4</sup>

Expressed on the surface of natural killer (NK) cells, *KIR* serve to mediate cytolytic killing and cytokine secretion.<sup>5</sup> The *KIR* gene complex on human chromosome 19q13.4 encodes both inhibitory and activating receptors, with significant variation in gene content between individuals and populations. Any given *KIR* haplotype may contain from 4 to 14 genes, and are generally categorized into two groups, termed A and B.<sup>6</sup> *KIR* molecules recognize specific epitopes on *HLA* class I: *KIR3DL2* and *KIR2DS4* recognize *HLA-A* molecules with the A3/A11 epitope, while *KIR2DL1*, *KIR2DL2/3*, *KIR2DS1*, *KIR2DS2* and *KIR2DS4* interact with either the C1 or C2 epitopes on *HLA-C*; a small subset of *HLA-B* molecules also carry the C1 epitope, and are capable of interacting with these KIR. Finally, *KIR3DL1* binds *HLA-A* and *-B* molecules that carry the Bw4 specificity.<sup>2,7–9</sup>

Only a handful of studies have been conducted examining *KIR* variation in MS, but overall, the analysis of *KIR* gene-content variation has pointed to a role for the *KIR* in disease susceptibility. In patients of European ancestry, predisposition to MS has been variably associated with the absence of the inhibitory *KIR2DL3* (ref. 10) or the presence of activating *KIR2DL5* and *KIR3DS1*. In other studies, *KIR2DS1* was found to be protective in MS.<sup>11,12</sup> In the largest previous study to-date, the *HLA* class I Bw4 motif was found

to be protective in a Norwegian cohort, but no association was observed between *KIR* carrier frequencies and MS.<sup>13</sup>

All prior examination of the role of *KIR* in MS has been conducted in cohorts of European origin. While conventional wisdom has held that MS is much less common in African Americans relative to European Americans, more recent data suggests that risk for MS in African Americans is higher than expected and its incidence in this group is increasing.<sup>14,15</sup> Importantly, African Americans are more likely to have a more acute disease course and it appears that this increased severity is partially associated with African ancestry.<sup>16,17</sup> Examination of *HLA* associations with MS in African Americans has served to clarify *HLA* class II haplotypic associations<sup>18</sup> and revealed a role for *HLA-DRB5*.<sup>19</sup> Here, we investigate the role of the *KIR* loci and their *HLA* class I ligands in a large cohort of African American MS patients and controls. In addition to being the first investigation of *KIR* and autoimmune disease in African Americans, this study represents the largest case-control analysis conducted to-date in any population examining *KIR* and *HLA* variation in MS.

## RESULTS AND DISCUSSION

No significant difference in carrier frequencies for any *KIR* locus (or allele in the case of *KIR2DL2/3* and *KIR3DL1/S1*), were observed between cases and controls (Table 1). We also examined whether specific haplotypic structures of the *KIR* were associated, rather than individual loci, both across the entire *KIR* cluster and within each of the centromeric and telomeric regions. No significant associations were observed for any specific *KIR* gene-content haplotype or particular combinations of *KIR* A and B haplotypes (data not shown).

<sup>1</sup>Department of Neurology, University of California, San Francisco, CA, USA; <sup>2</sup>Department of Laboratory Medicine and Pathology, Mayo Clinic in Arizona, AZ, USA and <sup>3</sup>ATIP-Avenir Inserm Unit 1064, Hospital and University of Nantes, Nantes, France. Correspondence: Dr JA Hollenbach, Department of Neurology, University of California, San Francisco School of Medicine, 675 Nelson Rising Lane, Mission Bay Campus, San Francisco, CA 94158, USA.

E-mail: jill.hollenbach@neurology.ucsf.edu

Received 6 November 2015; revised 16 December 2015; accepted 21 December 2015; published online 11 February 2016

However, examination of *KIR* in the context of their cognate *HLA* ligands (Table 2) revealed a strong protective effect for *KIR3DL1* in combination with *HLA-A* and *-B* alleles bearing the *Bw4* motif ( $P=10^{-8}$ ; odds ratio (OR)=0.60, confidence interval (CI)=0.50–0.71). Because nearly every individual in this cohort is positive for *KIR3DL1* (Table 1), a protective effect is also expected and observed for the *Bw4* ligand alone (Table 3;  $P < 10^{-6}$ ; OR=0.63, CI=0.53–0.75). These results are in keeping with those observed in the Norwegian cohort,<sup>13</sup> where, as in most populations<sup>20</sup> the carrier frequency of *KIR3DL1* is also very high. No other *HLA* ligand was independently associated with disease.

We tested all *HLA-B* alleles for association with disease in order to determine whether the *Bw4*-mediated effect could be attributed to one or a few specific *HLA-B* alleles. Only one *HLA-B* allele, *HLA-B\*53* would be considered significantly protective in this cohort after Bonferroni correction for multiple tests ( $< 0.002$ ). While this allele does have the *Bw4* motif, it is not present at sufficient frequency in this cohort ( $< 4\%$  in cases and controls; Supplementary Table 1) to account for the observed *Bw4* association. We therefore considered whether the observed association with *Bw4* could be attributed to linkage disequilibrium of *Bw4*-bearing *HLA-B* alleles with specific MS-associated *HLA* alleles at other loci.

When two locus haplotypes (*HLA-B*~*HLA-DRB1* and *HLA-A*~*HLA-B*) are considered with *HLA-B* alleles coded for either the *Bw4* or *Bw6* motif, in each case the most significantly protective haplotype bears a *Bw4* *HLA-B* allele, while the *HLA-A* and *HLA-DRB1* alleles vary (Table 4). For example, when *HLA-DRB1* is considered alone, protection is conferred by the common allele *HLA-DRB1\*11* ( $P=0.0001$ ; OR=0.69, CI=0.57–0.84). Likewise, the most highly

significant protective *HLA-DRB1*~*HLA-Bw4/6* haplotype is *HLA-DRB1\*11*~*Bw4* ( $P < 10^{-6}$ ; OR=0.50, CI=0.34–0.72). In contrast, the *HLA-DRB1\*11*~*Bw6* haplotype is not significantly associated with disease. Similarly, the two other haplotypes observed to be protective in this cohort are *HLA-DRB1\*13*~*Bw4* ( $P < 0.05$ ; OR=0.67, CI=0.49–0.93) and *HLA-DRB1\*07*~*Bw4* ( $P < 0.05$ ; OR=0.58, CI=0.40–0.85), but their *Bw6*-bearing counterparts are not. In each of these cases, the *Bw4* and *Bw6* bearing *HLA-DRB1* haplotypes are present at roughly equal frequencies, thus ruling out linkage disequilibrium as a source of the disparate effects.

When we consider common (frequency  $> 0.03\%$ ) haplotypes with *HLA-A*, only *HLA-A\*02*~*Bw4* is significantly protective in this cohort ( $P=0.003$ ; OR=0.70, CI=0.55–0.88). When *HLA-A* is considered alone (Supplementary Table 1), *HLA-A\*02* is not protective, nor is it protective in the context of *Bw6* rather than *Bw4* bearing *HLA-B* alleles (Table 4). Taken together, the haplotype data indicate that the protective effect is being mediated by the presence of the *Bw4* epitope that confers *KIR3DL1* ligand status to

**Table 1.** KIR carrier frequencies in MS cases and controls

<i>KIR</i>	Case	Control
2DL1	0.98	0.97
2DL2	0.54	0.53
2DL3	0.89	0.88
2DL4	1	1
2DL5	0.53	0.54
2DP1	0.99	0.98
2DS1	0.21	0.23
2DS2	0.47	0.46
2DS3	0.30	0.26
2DS4	0.98	0.98
2DS5	0.31	0.34
3DL1	0.98	0.98
3DS1	0.17	0.18
3DL2	1	1
3DL3	1	1
3DP1	1	1

Abbreviation: KIR, killer immunoglobulin-like.

**Table 2.** Frequency of *KIR*~*HLA* ligand combinations in MS cases and controls

<i>KIR</i> ~ <i>HLA</i> combination	Case	Control	P-value
<i>KIR2DL1</i> ~ <i>HLA-C2</i>	0.72	0.74	NS
<i>KIR2DL2</i> ~ <i>HLA-C1</i>	0.38	0.38	NS
<i>KIR2DL3</i> ~ <i>HLA-C1</i>	0.62	0.61	NS
<i>KIR3DL1</i> ~ <i>HLA-Bw4</i>	0.62	0.73	$10^{-8}$
<i>KIR3DL2</i> ~ <i>HLA-A3/11</i>	0.17	0.13	NS

Abbreviations: *HLA*, human leukocyte antigen; *KIR*, killer immunoglobulin-like; NS, nonsignificant.

**Table 3.** Carrier frequency of *HLA* ligands in MS cases and controls

Ligand	Case	Control	P-value
<i>HLA-C1</i>	0.69	0.70	NS
<i>HLA-C2</i>	0.74	0.76	NS
<i>HLA-Bw4</i>	0.64	0.74	$< 10^{-6}$
<i>HLA-A3/11</i>	0.17	0.13	NS

Abbreviations: *HLA*, human leukocyte antigen; NS, nonsignificant.

**Table 4.** *HLA-DRB1*~*HLA-B* and *HLA-A*~*HLA-B* haplotype frequencies in MS cases and controls

	<i>HLA-B</i>	Case	Control	P-value
<i>HLA-DRB1</i>				
<i>HLA-HLA-DRB1*03</i>	<i>Bw6</i>	0.136	0.112	0.004
<i>HLA-HLA-DRB1*13</i>	<i>Bw6</i>	0.085	0.083	NS
<i>HLA-HLA-DRB1*13</i>	<i>Bw4</i>	0.064	0.081	0.035
<i>HLA-HLA-DRB1*15:03</i>	<i>Bw6</i>	0.085	0.060	0.004
<i>HLA-HLA-DRB1*11</i>	<i>Bw6</i>	0.059	0.070	NS
<i>HLA-HLA-DRB1*11</i>	<i>Bw4</i>	0.038	0.065	$< 10^{-4}$
<i>HLA-HLA-DRB1*15:03</i>	<i>Bw4</i>	0.047	0.058	NS
<i>HLA-HLA-DRB1*07</i>	<i>Bw6</i>	0.050	0.050	NS
<i>HLA-HLA-DRB1*07</i>	<i>Bw4</i>	0.039	0.054	0.015
<i>HLA-HLA-DRB1*15:01</i>	<i>Bw6</i>	0.057	0.029	$< 10^{-6}$
<i>HLA-HLA-DRB1*01</i>	<i>Bw6</i>	0.042	0.038	NS
<i>HLA-HLA-DRB1*08</i>	<i>Bw6</i>	0.039	0.031	NS
<i>HLA-HLA-DRB1*04</i>	<i>Bw6</i>	0.030	0.035	NS
<i>HLA-HLA-DRB1*08</i>	<i>Bw4</i>	0.033	0.031	NS
<i>HLA-HLA-DRB1*03</i>	<i>Bw4</i>	0.032	0.027	NS
<i>HLA-A</i>				
<i>HLA-A*02</i>	<i>Bw6</i>	0.172	0.155	NS
<i>HLA-A*02</i>	<i>Bw4</i>	0.105	0.140	0.003
<i>HLA-A*03</i>	<i>Bw6</i>	0.096	0.070	0.01
<i>HLA-A*30</i>	<i>Bw6</i>	0.077	0.082	NS
<i>HLA-A*01</i>	<i>Bw6</i>	0.086	0.063	0.02
<i>HLA-A*23</i>	<i>Bw6</i>	0.069	0.069	NS
<i>HLA-A*30</i>	<i>Bw4</i>	0.041	0.054	NS
<i>HLA-A*03</i>	<i>Bw4</i>	0.057	0.040	0.02
<i>HLA-A*23</i>	<i>Bw4</i>	0.042	0.045	NS
<i>HLA-A*01</i>	<i>Bw4</i>	0.034	0.031	NS

Abbreviations: *HLA*, human leukocyte antigen; NS, nonsignificant. The 15 most common *HLA-DRB1*~*HLA-B* and 10 most common *HLA-A*~*HLA-B* (frequency  $> 3\%$ ) haplotypes are given.

**Table 5.** Frequency of KIR3DL1~Bw4 combination in *HLA-DRB1\*15:01* negative MS cases (*n* = 784) and controls (*n* = 1357)

	Case	Control
<i>KIR3DL1</i> ~ <i>Bw4</i> positive	0.639	0.744
<i>KIR3DL1</i> ~ <i>Bw4</i> negative	0.361	0.256

*HLA-B* alleles. The observed effect cannot be explained by either a specific *HLA-B* allele defined with respect to the antigen-binding domain (at single-field resolution) or by any protective *HLA-DRB1* or *HLA-A* alleles in linkage disequilibrium with Bw-bearing *HLA-B* alleles, supporting the relevance of the *KIR-HLA* framework in disease risk.

The strong predisposing effect of *HLA-DRB1\*15:01* in MS has long been recognized, and in this cohort *HLA-DRB1\*15:01*, like nearly most others examined to-date,<sup>21</sup> is the primary predisposing *HLA* variant with OR > 2 (Supplementary Table 1). Given the strong and significant role for *HLA-DRB1\*15:01*, we explored whether protection mediated via *KIR3DL1/HLA-Bw4* is differentially associated with regard to *HLA-DRB1\*15:01* status. Cases and controls were stratified according to having 0, 1 or 2 copies of *HLA-DRB1\*15:01*, and association of *KIR3DL1/Bw4* with disease was examined within each stratum (Table 5). The protective effect was observed only in individuals who were not positive for *HLA-DRB1\*15:01* ( $P < 10^{-6}$ ; OR = 0.61, CI = 0.51–0.74). These data suggest that while the *KIR*-ligand combination mediates a robust protective effect, that effect is overridden in the presence of the strong predisposing effect of *HLA-DRB1\*15:01*. Analysis of *HLA-B*~*HLA-DRB1* haplotypes in *HLA-DRB1\*15:01*-negative individuals yields results similar to those described above for the entire cohort (data not shown), implying that differential association of *KIR3DL1/Bw4* is not mediated by linkage disequilibrium between *HLA-DRB1* and *HLA-B* alleles.

Given the extensive allelic polymorphism of *KIR3DL1*, future studies examining *KIR* in MS will benefit from high-resolution genotyping, particularly in populations with African ancestry. For example, a non-expressed variant, *KIR3DL1\*004* (ref. 22) is observed at relatively high frequencies in a West African population.<sup>23</sup> It is also interesting to note that *KIR3DL1* and *HLA-Bw4* were found to be subject to co-evolution in this same population, suggesting a selective advantage for this *KIR-HLA* combination.

In conclusion, our data in a large African American cohort confirm and refine a previous finding in a large Norwegian cohort<sup>13</sup> of protection from MS mediated by the *KIR3DL1* ligand *HLA-Bw4*, either alone or in combination with *KIR3DL1*. The fact that our results in a large African American cohort also implicate Bw4, despite the fact that individuals with European and African ancestry have vastly different *HLA-B* allelic variation and frequency distributions,<sup>24</sup> supports the notion that the functional properties of the Bw4 motif with respect to *KIR3DL1* and NK cell inhibition and/or licensing are the key determinants in protection from disease.

## MATERIALS AND METHODS

The study cohort consisted of 907 African American MS cases and 1456 African American controls. All multiple sclerosis subjects met established diagnostic criteria.<sup>25,26</sup> Ascertainment protocols and clinical and demographic characteristics have been summarized elsewhere.<sup>16,18</sup> Principal component analysis and pruned genome-wide autosomal non-major histocompatibility complex (MHC) single nucleotide polymorphisms (SNPs) with minor allele frequency > 1% were used to assess ancestry and control for the effects of population stratification.<sup>27</sup>

## KIR genotyping

DNA samples were collected from patients and *KIR* typing was performed for presence or absence of *KIR* genes by the LABType SSO *KIR* typing (OneLambda, Inc., Canoga Park, CA, USA). The typing system can distinguish 8 inhibitory genes (*KIR2DL1-2DL5* and *KIR3DL1-3DL3*), 6 activating genes (*KIR2DS1-2DS5* and *KIR3DS1*) and 2 pseudogenes (*KIR2DP1* and *KIR3DP1*).

## HLA genotyping

Genotypes for *HLA-DRB1*, *HLA-A*, *-B* and *-C* were obtained by sequence specific oligonucleotide probes using the LABType SSO *HLA* typing (OneLambda, Inc.).

## Statistical analysis

All statistical analysis was performed using the R language for statistical computing.<sup>28</sup> All single-locus tests for association were performed using standard chi-squared analysis with the 'chisq.test' function in the R base package. Odds ratios and confidence intervals were calculated using the 'epitools' package for R.<sup>29</sup> In the case of low-frequency cells, as is common in *HLA* data, alleles with expected counts < 5 were combined into a single 'binned' category prior to analysis.<sup>30</sup> Haplotype estimation and association tests were performed using the 'haplo.stats' package.<sup>31,32</sup>

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## ACKNOWLEDGEMENTS

The authors thank the multiple sclerosis patients and healthy controls who participated in this study. We also thank Nezhil Cereb and Soo Young Yang at Histogenetics Inc., and Hanne Harbo for useful discussion. This study was supported by grants from the National Institute of Health (R01NS046297 and U19NS095774). Recruitment of study participants and sample acquisition was supported by the National Multiple Sclerosis Society (RG2899-D11).

## REFERENCES

- Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M *et al*. *HLA-C*-dependent prevention of leukemia relapse by donor activating *KIR2DS1*. *N Engl J Med* 2012; **367**: 805–816.
- Parham P, Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. *Nat Rev Immunol* 2013; **13**: 133–144.
- Bashirova AA, Thomas R, Carrington M. *HLA/KIR* restraint of HIV: surviving the fittest. *Annu Rev Immunol* 2011; **29**: 295–317.
- Altfeld M, Fadda L, Frleta D, Bhardwaj N. DCs and NK cells: critical effectors in the immune response to HIV-1. *Nat Rev Immunol* 2011; **11**: 176–186.
- Biron CA. Activation and function of natural killer cell responses during viral infections. *Curr Opin Immunol* 1997; **9**: 24–34.
- Parham P. Influence of *KIR* diversity on human immunity. *Adv Exp Med Biol* 2005; **560**: 47–50.
- Colonna M, Moretta A, Vely F, Vivier E. A high-resolution view of NK-cell receptors: structure and function. *Immunol Today* 2000; **21**: 428–431.
- Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A. Surface NK receptors and their ligands on tumor cells. *Semin Immunol* 2006; **18**: 151–158.
- Kaur G, Trowsdale J, Fugger L. Natural killer cells and their receptors in multiple sclerosis. *Brain* 2013; **136**(Pt 9): 2657–2676.
- Jelicic I, Hsu KC, Kakalacheva K, Breiden P, Dupont B, Uhrberg M *et al*. Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis. *Mult Scler* 2012; **18**: 951–958.
- Bettencourt A, Silva AM, Carvalho C, Leal B, Santos E, Costa PP *et al*. The role of *KIR2DS1* in multiple sclerosis–*KIR* in Portuguese MS patients. *J Neuroimmunol* 2014; **269**: 52–55.
- Fusco C, Guerini FR, Nocera G, Ventrella G, Caputo D, Valentino MA *et al*. *KIRs* and their *HLA* ligands in remitting-relapsing multiple sclerosis. *J Neuroimmunol* 2010; **229**: 232–237.
- Lorentzen AR, Karlsen TH, Olsson M, Smestad C, Mero IL, Woldseth B *et al*. Killer immunoglobulin-like receptor ligand *HLA-Bw4* protects against multiple sclerosis. *Ann Neurol* 2009; **65**: 658–666.

- 14 Wallin MT, Culpepper WJ, Coffman P, Pulaski S, Maloni H, Mahan CM *et al*. The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service. *Brain* 2012; **135**(Pt 6): 1778–1785.
- 15 Langer-Gould A, Brara SM, Beaver BE, Zhang JL. Incidence of multiple sclerosis in multiple racial and ethnic groups. *Neurology* 2013; **80**: 1734–1739.
- 16 Cree BA, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA *et al*. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. *Neurology* 2004; **63**: 2039–2045.
- 17 Cree BA, Reich DE, Khan O, De Jager PL, Nakashima I, Takahashi T *et al*. Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. *Arch Neurol* 2009; **66**: 226–233.
- 18 Oksenberg JR, Barcellos LF, Cree BA, Baranzini SE, Bugawan TL, Khan O *et al*. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. *Am J Hum Genet* 2004; **74**: 160–167.
- 19 Caillier SJ, Briggs F, Cree BA, Baranzini SE, Fernandez-Vina M, Ramsay PP *et al*. Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. *J Immunol* 2008; **181**: 5473–5480.
- 20 Hollenbach JA, Ncedal I, Ladner MB, Single RM, Trachtenberg EA. Killer cell immunoglobulin-like receptor (KIR) gene content variation in the HGDP-CEPH populations. *Immunogenetics* 2012; **64**: 719–737.
- 21 Hollenbach JA, Oksenberg JR. The immunogenetics of multiple sclerosis: A comprehensive review. *J Autoimmun* 2015; **64**: 13–25.
- 22 Pando MJ, Gardiner CM, Gleimer M, McQueen KL, Parham P. The protein made from a common allele of KIR3DL1 (3DL1\*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. *J Immunol* 2003; **171**: 6640–6649.
- 23 Norman PJ, Hollenbach JA, Nemat-Gorgani N, Guethlein LA, Hilton HG, Pando MJ *et al*. Co-evolution of Human Leukocyte Antigen (HLA) Class I Ligands with Killer-Cell Immunoglobulin-Like Receptors (KIR) in a Genetically Diverse Population of Sub-Saharan Africans. *PLoS Genet* 2013; **9**: e1003938.
- 24 Fernandez Vina MA, Hollenbach JA, Lyke KE, Sztein MB, Maiers M, Klitz W *et al*. Tracking human migrations by the analysis of the distribution of HLA alleles, lineages and haplotypes in closed and open populations. *Philos Trans R Soc Lond B Biol Sci* 2012; **367**: 820–829.
- 25 McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD *et al*. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. *Ann Neurol* 2001; **50**: 121–127.
- 26 Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M *et al*. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol* 2011; **69**: 292–302.
- 27 Isobe N, Madireddy L, Khankhanian P, Matsushita T, Caillier SJ, More JM *et al*. An ImmunoChip study of multiple sclerosis risk in African Americans. *Brain* 2015; **138**(Pt 6): 1518–1530.
- 28 R Development Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing: Vienna, Austria, 2008.
- 29 Aragon T. *epitools: Epidemiology Tools*. R package version 0.5-7, 2012.
- 30 Hollenbach JA, Mack SJ, Thomson G, Gourraud PA. Analytical methods for disease association studies with immunogenetic data. *Methods Mol Biol* 2012; **882**: 245–266.
- 31 Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. *Am J Hum Genet* 2002; **70**: 425–434.
- 32 Sinnwell J, Schaid D. *haplo.stats: Statistical Analysis of Haplotypes with Traits and Covariates when Linkage Phase is Ambiguous*. R package version 1.7.1, 2015.

Supplementary Information accompanies this paper on Genes and Immunity website (<http://www.nature.com/gene>)